Ionis Pharmaceuticals
IONS
285 hedge funds and large institutions have $6.4B invested in Ionis Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 66 funds opening new positions, 91 increasing their positions, 93 reducing their positions, and 18 closing their positions.
267% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 18
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
56% more capital invested
Capital invested by funds: $4.1B → $6.4B (+$2.3B)
19% more funds holding
Funds holding: 240 → 285 (+45)
2% less repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 93
18% less call options, than puts
Call options by funds: $115M | Put options by funds: $141M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$76.9M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$29.3M |
| 3 |
BG
BlackRock Group
London,
United Kingdom
|
+$20.4M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$18.9M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$17.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$173M |
| 2 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
-$35.4M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$32.6M |
| 4 |
TAM
Tocqueville Asset Management
New York
|
-$18M |
| 5 |
SI
Scout Investments
Kansas City,
Missouri
|
-$17.4M |
IONS Hedge Fund Activity: Q4 2014 in Review
285 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2014, worth a combined $6.4B — up 56% from $4.1B a quarter earlier.
Buyers outnumbered sellers: 66 funds opened new IONS positions and 18 closed out — a net gain of 48 holders — while 91 added to existing stakes and 93 trimmed.
The largest buyer was First Trust Advisors, opening a new position worth an estimated $76.9M. The largest seller was Artisan Partners, cutting an estimated $173M.
- 285 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2014, up from 240 in Q3 2014.
- Funds reported $6.4B of Ionis Pharmaceuticals stock for Q4 2014, up 56% quarter-over-quarter.
- 66 funds opened new Ionis Pharmaceuticals positions in Q4 2014 and 18 closed out, a net change of +48 holders.
- The largest Ionis Pharmaceuticals buyer in Q4 2014 was First Trust Advisors, an estimated $76.9M added.
- The largest Ionis Pharmaceuticals seller in Q4 2014 was Artisan Partners, an estimated $173M sold.
Based on aggregated 13F filings for Q4 2014.